Search Results
Your search for ,ShE matches 5598 pages
Showing 2751 - 2800Expert Point of View: Oreofe Olukemi Odejide, MD, MPH
Discussant of the abstract by Rao et al, Oreofe Olukemi Odejide, MD, MPH, a medical oncologist at Dana-Farber Cancer Institute, Boston, underscored the issues associated with intense health-care utilization near the end of life. “Several studies have shown that intense health-care utilization...
Adetokunbo 'Toks' Oluwasanjo, MD, Joins Florida Group
Medical oncologist/hematologist Adetokunbo ‘Toks’ Oluwasanjo, MD, has joined Florida Cancer Specialists (FCS) in the new FCS Lake City office. For 3 years, she served on the faculty in the Department of Medicine of the Reading Health System (now Tower Health System). Dr. Toks received her medical...
Despite Challenges, Pioneer in CT Screening for Early Lung Cancer Works to Move the Field Forward
In 1999, a team of researchers from Weill Cornell Medical College advocated the use of a then-novel practice: low-dose radiation CT screening for lung cancer. It captures a full thoracic image in a single breath hold, and can recognize a tumor in its earliest stages when the chance for cure is...
A Call to Action for Oncology Clinicians to Help Patients ‘Move Through Cancer’
“There is clear evidence that patients are more likely to exercise if their oncologist tells them to do so,” reported representatives from 17 organizations participating in the Second Roundtable on Exercise and Cancer Prevention and Control. In an article published in CA: A Cancer Journal for...
Stanford Medicine Division of Oncology Welcomes Three New Faculty Members
The Stanford Medicine Department of Medicine is excited to welcome three faculty members to its Division of Oncology: Curtis Chong, MD, PhD; Fauzia Riaz, MD; and Shagufta Shaheen, MD. Each of these individuals brings an impressive record of academic pursuits focused on advancing care for and...
ACCC Presents Annual Achievement Award Posthumously to Arti Hurria, MD, FASCO
The 2019 Association of Community Cancer Centers (ACCC) Annual Achievement Award was presented posthumously to Arti Hurria, MD, FASCO, of City of Hope. The oncology community experienced a devastating loss with the untimely passing of Dr. Hurria in November 2018. Dr. Hurria was the George Tsai...
A Need for Human Connection Led to a Rewarding Career in Geriatric Oncology for Lodovico Balducci, MD
Older adults are the fastest-growing segment of our population, and more than 65% of patients with newly diagnosed cancer are 65 years of age or older. Although we now recognize the special needs of older patients with cancer, the field of geriatric oncology emerged quietly, with early growing...
Expert Point of View: Marleen Kok, MD
“This is currently the largest data set with information on retreatment,” said formal study discussant Marleen Kok, MD, of the Netherlands Cancer Institute, Amsterdam, The Netherlands. She noted there was a partial response in 11% and stable disease in 60%. “Upon initial treatment, partial...
An Oncologist’s Thoughtful Examination of Cancer and Personal Loss
“I could not have written this book when I was 30 years old. It is not because of any great discoveries I have made or research papers I have published since. It is because of the experience the intervening decades have given me as I cared for thousands of cancer patients and accompanied many to...
Navneet S. Majhail, MD, MS, Was Inspired by His Father’s Career as a Military Doctor and His Mother’s Battle With Cancer
In this installment of the Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Navneet S. Majhail, MD, MS, about his journey from India to the Cleveland Clinic, where he is Director of the Blood and Marrow Transplant Program. He is also President of the American Society for...
2019 Mary Pazdur Award for Excellence in Advanced Practice in Oncology
The Advanced Practitioner Society for Hematology and Oncology (APSHO) recently awarded the 2019 Mary Pazdur Award for Excellence in Advanced Practice in Oncology to Jody Pelusi, PhD, FNP, AOCNP (center). Dr. Pelusi is with HonorHealth Research Institute in Scottsdale. The award was presented...
With a Little Help From My Friends: Social Support Linked to Pain Reduction in Patients With Cancer
Pain may be one of the most common symptoms experienced by patients with cancer, but researchers are still unpacking its mysteries, with some surprising results. According to data presented at the 2019 Supportive Care in Oncology Symposium,1 greater social support may help mitigate pain in patients ...
Expert Point of View: Arndt Vogel, MD and Angela Lamarca, MD, PhD
Arndt Vogel, MD, of Hannover Medical School in Germany, who served as discussant of the two studies of immunotherapy in hepatocellular carcinoma, said the findings point to a promising future in the treatment of this malignancy. He commented that the responses observed with nivolumab in CheckMate...
MD Anderson Names New Senior Vice President and Chief Legal Officer
The University of Texas MD Anderson Cancer Center has named Allyson Hancock Kinzel, JD, as Senior Vice President and Chief Legal Officer, effective November 1, 2019. Ms. Kinzel takes on this new role leading legal and regulatory affairs after serving as Chief Legal Officer since 2018. She will...
Maximizing Benefit in the Treatment of Immune-Mediated Colitis
Immune-related colitis is the second most common toxicity associated with checkpoint inhibitors, affecting up to 40% of patients. The ASCO Post interviewed Yinghong Wang, MD, PhD, Director of Medication-Induced Colitis and Enteritis, Director of Fecal Microbiota Transplantation, and Associate...
Confirmation Hearing for FDA Commissioner Nominee Stephen Hahn, MD
On November 20, 2019, Stephen Hahn, MD, President Trump’s nominee to be the next Commissioner of the U.S. Food and Drug Administration (FDA), appeared before the Senate Health, Education, Labor, and Pension Committee and answered wide-ranging questions relating to the many important roles the...
City of Hope’s Michael Caligiuri, MD, Formally Appointed to Deana and Stave Campbell Physician-in-Chief Distinguished Chair
Michael A. Caligiuri, MD, President of City of Hope National Medical Center, in Duarte, California, has been appointed the Deana and Steve Campbell Physician-in-Chief Distinguished Chair in Honor of Alexandra Levine, MD. The position was created in honor of Dr. Levine, a City of Hope Professor of...
Breast Cancer Treatments Targeting Estrogen May Be Putting Patients at Risk for Long-Term Comorbidities
“The majority of breast cancers are hormone receptor–positive, and treatments that target the estrogen receptors are very effective, but they also cause havoc in many tissues that are dependent on estrogen for normal functioning. As a result, breast cancer survivors suffer from ongoing symptoms and ...
Challenging the Global Community to Deliver Equitable Cancer Care for All
For Her Royal Highness Princess Dina Mired of Jordan, ensuring that every patient with cancer receives high-quality care is not an abstract goal—it is personal. Princess Dina saw firsthand the life-and-death differences that access to state-of-the-art oncology care makes in a patient’s life when...
Nivolumab/Ipilimumab: Another First-Line Option for Advanced NSCLC
The combination of nivolumab and ipilimumab improved overall survival compared with chemotherapy as first-line therapy for patients with advanced non–small cell lung cancer (NSCLC) and programmed cell death ligand 1 (PD-L1) expression of at least 1%, according to the results of CheckMate 227....
What Is the Best Palliation for End-Stage Lung Cancer?
Patients with advanced lung cancer can experience burdensome symptoms at the end of life. Pulmonologists can alleviate some of this suffering, but it’s a balancing act between doing too much and not enough, according to specialists who spoke at CHEST 2019, the annual meeting of the American College ...
Study Finds Sexual Health Issues Are a Concern Among Majority of Women With Breast Cancer
Endocrine therapy has been a lifesaver for women with estrogen receptor–positive breast cancer, but decreases in recurrence and cancer-related mortality have come with substantial side effects, according to data presented at the 2019 Supportive Care in Oncology Symposium.1 The results of a...
Maximizing Benefit in the Treatment of Immune-Mediated Colitis
Immune-related colitis is the second most common toxicity associated with checkpoint inhibitors, affecting up to 40% of patients. The ASCO Post interviewed Yinghong Wang, MD, PhD, Director of Medication-Induced Colitis and Enteritis, Director of Fecal Microbiota Transplantation, and Associate...
ESMO Congress 2019: Quick Takes From Key Clinical Trials
The ESMO Congress continues to grow as a pivotal platform for research in clinical oncology. At the ESMO Congress 2019, important findings were showcased in more than 2,200 studies, including 93 late-breaking abstracts. The ASCO Post summarized much of that news in separate articles over several...
Expert Point of View: Eleni Efstathiou, MD
Formal study discussant Eleni Efstathiou, MD, of MD Anderson Cancer Center, Houston, commented on results of the PROfound trial at the ESMO Congress 2019. “This is the first phase III targeted therapy trial to deliver a positive outcome in metastatic castration-resistant prostate cancer,” she...
Phase III PROfound Study Evaluates Olaparib in Setting of Metastatic, Castration-Resistant Prostate Cancer
Treatment with the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib delayed disease progression and appears to improve survival, compared with newer hormonal agents in men with pretreated metastatic castration-resistant prostate cancer and homologous recombinant repair (HRR) genetic...
Expert Point of View: Nicoletta Colombo, MD
The invited discussant of the two trials in cervical and endometrial cancers presented at the ESMO Congress 2019 was Nicoletta Colombo, MD, of the University of Milan-Bicocca in Italy, who commented on what she called “exciting results in cancers with unmet needs.” Dr. Colombo noted: “The studies...
Immunotherapy Shows Strong Benefit in Two Gynecologic Cancers
In studies reported at the ESMO Congress 2019, immunotherapy yielded encouraging outcomes in two gynecologic cancer populations in need of new treatments, including patients with advanced cervical cancer that is microsatellite-stable and patients previously treated for advanced endometrial cancer. ...
CheckMate 227: Nivolumab Plus Ipilimumab Presents Another Option in First-Line Treatment of Advanced Non–Small Cell Lung Cancer
The combination of nivolumab and ipilimumab improved overall survival compared with chemotherapy as first-line therapy for patients with advanced non–small cell lung cancer (NSCLC) and programmed cell death ligand 1 (PD-L1) expression of at least 1%, according to the results of CheckMate 227....
Expert Point of View: Pilar Garrido, MD, PhD
At a press conference at the ESMO Congress 2019, Pilar Garrido, MD, PhD, of Ramon y Cajal University Hospital, Madrid, commented on the FLAURA trial: “These results are good news for patients with lung cancer, which is the most common cause of cancer deaths. Advances in the understanding of the...
Expert Point of View: Nicoletta Colombo, MD
The invited discussant of the two trials in cervical and endometrial cancers presented at the ESMO Congress 2019 was Nicoletta Colombo, MD, of the University of Milan-Bicocca in Italy, who commented on what she called “exciting results in cancers with unmet needs.” Dr. Colombo noted: “The studies...
Checkpoint Inhibitors Benefit Women With Advanced Stages of Cervical, Endometrial Cancers
Immunotherapy studies reported at the ESMO Congress 2019 yielded encouraging outcomes in patients with advanced cervical cancer that is microsatellite-stable and patients previously treated for advanced endometrial cancer. The combination of nivolumab and ipilimumab, with two different dosing...
MONALEESA-3, MONARCH 2: CDK4/6 Inhibitors Plus Fulvestrant Benefit Survival in Advanced Breast Cancer
CDK4/6 inhibitors improve overall survival in advanced breast cancer, according to results of two important phase III trials reported at the ESMO Congress 2019. Dennis J. Slamon, MD, PhD, of the University of California, Los Angeles Women’s Cancer Research Program, presented the findings from the...
Short-Term Survival in Patients Aged 85 Years and Older After Colorectal Cancer Surgery
Results from a preliminary research study showed the majority of patients aged 85 years and older were still alive in the short-term after undergoing segmental colectomy for stage II and III colon cancer. Kaur et al presented these findings at the American College of Surgeons Clinical Congress...
Advocates Urge Action on Cancer Care Access at ASCO Advocacy Summit
At the 2019 ASCO Advocacy Summit, ASCO members from 35 states held more than 160 Congressional meetings, urging members of Congress to take action to advance policy priorities that improve patient access to cancer care, including: The Covering Life-Saving Investigations Needed in Cancer and Other...
Expert Point of View: Ana Oaknin, MD, PhD
Ana Oaknin, MD, PhD, Head of the Gynecologic Cancer Program at Vall d’Hebron Institute of Oncology, Barcelona, discussed the PRIMA/ENGOT-OV26/GOG-3012 trial along with the results of the phase III PAOLA-1/ENGOT-ov25 trial of olaparib plus bevacizumab maintenance. According to Dr. Oaknin, the...
How Clonal Hematopoiesis of Indeterminate Potential Increases the Risk of Heart Disease and Blood Cancers as People Age
Although stem cells throughout the body acquire genetic mutations over time, usually these alterations do not affect how the stem cells function or cause disease. However, recent research in clonal hematopoiesis and aging has found an association between clonal expansion of hematopoietic cells with ...
Cleveland Clinic Names Halle Moore, MD, Director of Breast Medical Oncology, Adds New Staff Physicians
Halle Moore, MD, has been named Director of Breast Medical Oncology and Co-Director for the Comprehensive Breast Cancer Program at Cleveland Clinic. She will start her role in January 2020. Dr. Moore joined Cleveland Clinic in 1999 and specializes in the medical management of breast cancer. Her...
Early Lung Cancer Detection Followed by Minimally Invasive Surgery Saves Lives
Lung cancer remains the number one cancer killer, leading to about 150,000 deaths per year in the United States and accounting for approximately 25% of all cancer deaths in the nation. Early detection has improved survival in other malignancies such as breast, colon, and cervical cancers, but...
The Oncology Care Model and Quality of Care: Defining, Measuring, and Implementing New Approaches to Cancer Care
The Oncology Care Model was instituted in 2016 by the Center for Medicare & Medicaid Innovation as a move away from the fee-for-service payment model and toward value-based care. It has sparked discussion ever since. How should quality be defined? Whose and what values should it reflect? How...
Expert Point of View: Silke Gillessen, MD
Formal discussant Silke Gillessen, MD, of the Division of Cancer Sciences, University of Manchester, United Kingdom, agreed that this study is practice-changing. “The study was well designed and addressed an unmet clinical need that is commonly seen in the clinic. Until now we had no randomized...
ASTRO Honors 2019 Gold Medalists, Honorary Member, and Other Award Recipients
The American Society for Radiation Oncology (ASTRO) recognized the recipients of its 2019 Gold Medal awards and other high-profile honors at the 2019ASTRO Annual Meeting. Gold Medalists and Honorary Member Walter J. Curran, Jr, MD;Silvia C. Formenti, MD, FASTRO; and Thomas R. Mackie, PhD, were...
LEAD Conference Awards 2019 Woman Oncologist of the Year
Claire Verschraegen, MD, was named the 2019 Woman Oncologist of the Year, and Shikha Jain, MD, FACP, received the 2019 Rising Star award at the first-ever Leadership Empowerment and Development: Enriching Experiences for Women in Hematology and Oncology (LEAD) Conference, hosted by Bio Ascend. An ...
Expert Point of View: Mafalda Oliveira, MD, PhD
Formal discussant Mafalda Oliveira, MD, PhD, of Vall d’Hebron Institute of Oncology in Barcelona, commented that monarcHER was a “well-designed, hypothesis-generating trial that addresses clinically relevant questions,” including whether cyclin-dependent kinase 4 and 6 inhibition now has broader...
Abemaciclib Benefits Patients With HER2-Positive Breast Cancer in monarcHER Trial
Inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) are associated with a robust benefit in patients with hormone receptor–positive, HER2-negative breast cancer, but now the monarcHER trial has confirmed their benefit in the HER2-positive population. The new findings were reported at the...
Studies Report Efficacy of Proton Radiotherapy for Hepatocellular Carcinoma
Two new studies published in the International Journal of Radiation Oncology • Biology • Physics focused on the use of proton radiation therapy to treat patients with hepatocellular carcinoma. The first study, by Sanford et al, found that proton radiation may extend overall survival compared to...
An Early Love of Nature’s Biodiversity Leads to a Career in Cancer Research for Lisa Coussens, PhD
Founded in 1887, the Oregon Health Sciences University (OHSU) is located in Portland, Oregon, and is home to the cutting-edge Coussens Lab, which focuses on the role of immune cells and their mediators as critical regulators of cancer development. The lab’s eponymous Director, Lisa Coussens, PhD,...
Expert Point of View: Ana Oaknin, MD, PhD
“The main goal in ovarian cancer is to avoid relapse after first-line therapy because otherwise, the probability of cure is quite low,” said European Society for Medical Oncology (ESMO) discussant of the PAOLA-1 trial, Ana Oaknin, MD, PhD, of the Vall d’Hebron Institute of Oncology, Barcelona....
Continuous Therapy for Multiple Myeloma Offers Survival Advantage, but Questions Remain
The number of approved agents in multiple myeloma has skyrocketed in recent years, leading to significant improvements in survival, but questions remain regarding the optimal duration of treatment. Although traditionally limited to a fixed number of cycles due to accumulating toxicity, novel agents ...
Expert Point of View: Eleni Efstathiou, MD
Formal study discussant Eleni Efstathiou, MD, of MD Anderson Cancer Center, Houston, was enthusiastic about the PROfound trial results. “This is the first phase III targeted therapy trial to deliver positive outcomes in metastatic castration-resistant prostate cancer,” she stated. “This is truly a ...
